Erasmus for Young Entrepreneurs

Opened

Code: 39631 | Identifier Code: SMP-COSME-2026-EYE | Programme name: 3856 | Start submission calls: 05/02/2026 | End submission calls: 21/04/2026

Erasmus for Young Entrepreneurs is a cross-border exchange programme designed to give new or aspiring entrepreneurs the opportunity to learn from seasoned entrepreneurs who are managing small businesses in other participating countries.

This programme not only provides experienced entrepreneurs with access to innovative ideas and skills, but also empowers new entrepreneurs to successfully launch their startups, fostering their development and ensuring their survival. In addition to developing essential business skills, participants benefit from expanding their operations, forging new business partnerships, and discovering new markets both within the Single Market and beyond.

The European Forest Institute (EFI) – Knowledge to Practice: Develop applications and AI solutions utilizing the ForestWard Observatory

Opened

Code: 39628 | Identifier Code: G-01-2026 | Programme name: 20613 | Start submission calls: 04/02/2026 | End submission calls: 03/04/2026

FORWARDS is a Horizon Europe project that will prototype the ForestWard Observatory, a pan-European monitoring and evaluation tool that will help demonstrate the impact of climate change on forests and guide decision-making for practical forest management.

Within the FORWARDS Horizon Europe project, forest data from different programs, projects and other initiatives are collected, with a focus on quantifying the impacts of climate change on forests. These datasets are collected by the forthcoming ForestWard Observatory, a pan-European monitoring and evaluation tool that will help demonstrate the impacts of climate change on forests and guide decisionmaking for practical forest management.

Support for social dialogue

Opened

Code: 39624 | Identifier Code: SOCPL-2026-SOC-DIALOG | Programme name: 2923 | Start submission calls: 21/01/2026 | End submission calls: 23/07/2026

This call aims at contributing to the promotion of social dialogue at cross-industry and sectoral level, developing European social dialogue, and building and strengthening the capacity of social partner organisations (both in Member States and candidate countries).

Projects to Support Maritime Spatial Planning (MSP)

Opened

Code: 39621 | Identifier Code: EMFAF-2026-PIA-MSP | Programme name: 13524 | Start submission calls: 15/01/2026 | End submission calls: 15/04/2026

The objective of this call for proposals is to facilitate sea basin cooperation on Maritime Spatial Planning in the EU, including through the effective implementation of Directive 2014/89 establishing a framework for MSP.

This call is intended to fund projects to develop innovative responses to tackle specific challenges that EU Member States might encounter when putting into effect, monitoring and/or revising their Maritime Spatial Plans.

NGI Zero Commons Fund 12th Open Call – “Reclaim the public nature of the internet”

Opened

Code: 39617 | Identifier Code: NGI0 Commons Fund | Programme name: 20613 | Start submission calls: 01/02/2026 | End submission calls: 01/04/2026

The goal of this new fund is to help deliver, mature and scale new internet commons across the whole technology spectrum, from libre silicon to middleware, from P2P infrastructure to convenient end user applications. We have a holistic, full-stack approach, simply because there is no other way. If we want to reclaim the public nature of the internet and yield the full benefits from technology as a society, we need to have full coverage — period.

Scaling up innovation in cardiovascular health

Opened

Code: 39613 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-15 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

CVDs are the main cause of death in the EU, with over 1.7 million deaths annually, costing about EUR 282 billion, or 11% of the healthcare budget.

With projections showing a rise in CVD prevalence and mortality by 2050 due to an aging population, the Commission is preparing a comprehensive EU Cardiovascular Health (CVH) plan to support Member States in their efforts to reduce the burden of CVDs.

The proposal is expected to support prevention, early detection, including via digital and personalised approaches.

Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

Opened

Code: 39610 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-11 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Cardiovascular diseases (CVDs) are the leading cause of premature deaths in the EU and account for 32% of all deaths in 2021 (over 1.7 million deaths).

Biological sex and gender play a specific role both in the incidence and the prevalence of certain diseases, including CVDs. Sex and gender disparities in CVDs are influenced by biological, behavioural, and sociocultural factors, affecting symptoms, prevalence, treatment, and outcomes. Hormonal influences, genetic predispositions, and/or physiological differences contribute to variations in how CVD presents and progresses in men and women. Risk factors such as diabetes, cholesterol, smoking, and age have different impacts across genders, highlighting the need for customised treatment strategies. Unique gender-specific conditions in women, such as menopause, pregnancy complications like preeclampsia and certain autoimmune diseases, also increase the risk for CVDs.

Mainstreaming a gender perspective into the research, prevention and control of CVDs is thus crucial to understanding and addressing the health risks and needs of women and men of all ages.

Although the significant progress has been done in investigating sex and/or gender-specific pathophysiological mechanisms of cardiovascular diseases, more research is needed to translate basic discoveries into the development of innovative prevention, detection, diagnosis, and treatment options.

Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

Opened

Code: 39607 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-09 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

The Commission is a member of the Global Alliance for Chronic Diseases (GACD).

The GACD specifically addresses NCDs and supports implementation research to improve health outcomes.

This topic is launched in concertation with the other GACD members (international funding agencies) and aligned with the 11^th GACD call.

Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Opened

Code: 39604 | Identifier Code: HORIZON-HLTH-2026-01-TOOL-07 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

ATMPs represent a frontier in medicine, offering groundbreaking treatments such as gene therapies, cell therapies, and tissue-engineered products that hold the promise of addressing complex and previously untreatable conditions.

The European ATMP landscape is dynamic and promising, with 28 products having received marketing authorisation and many more in the pipeline. The development of specialised infrastructures in Europe for these cutting-edge therapies is crucial for fostering innovation and ensuring fast and efficient delivery to patients in an equitable way.

The report by Mario Draghi on EU competitiveness, highlights that the EU’s share of the fast-growing global ATMP market is small, suggesting that to remain competitive, increased and focused public R&D investment is needed to complement ongoing efforts to streamline regulations and ensure faster pricing and reimbursement.

The report recommends building on existing innovation hubs and expanding the capacity of the EU to conduct ATMPs R&D by the consolidation of EU public funds. By strengthening this budding innovation ecosystem, Europe can position itself as a leader in the ATMP sector, ultimately improving patient access to life-saving treatments and stimulating economic growth.

Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Opened

Code: 39601 | Identifier Code: HORIZON-HLTH-2026-01-TOOL-06 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

This topic aims to coordinate and develop the new European Research Area (ERA) policy action to accelerate, through an aligned and coordinated approach across Member States and Associated Countries, the development, validation/qualification, acceptance, and uptake of NAMs in biomedical research and regulatory testing of medicinal products and medical devices as part of the ERA Policy Agenda 2025-2027.

Support for a multilateral initiative on climate change and health research

Opened

Code: 39598 | Identifier Code: HORIZON-HLTH-2026-01-ENVHLTH-05 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Climate-related health challenges are global and complex in nature, which calls for coordinated action bringing together different research disciplines, policy sectors, perspectives and approaches.

This requires seamless communication and synergies between different Research and Innovation (R&I) funding instruments.

Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine

Opened

Code: 39595 | Identifier Code: HORIZON-HLTH-2026-01-TOOL-05 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

R&I is essential for economic growth and boosting the competitiveness of the EU’s life sciences sector. Through the Horizon 2020 and Horizon Europe Framework Programmes, the EU has supported projects that significantly impact our health by fostering scientific discoveries and developing new solutions.

Transformational health innovations, such as mRNA vaccines, highlight the importance of collaboration among businesses, research institutions, and healthcare providers. Furthermore, sustained funding throughout the entire value chain is crucial for maximising impact and ensuring more products reach patients faster.

The main aim of this topic is to pilot a follow-on funding mechanism, supporting the stepwise development of biotech innovations through collaboration, resulting from previously supported EU R&I actions in the field of health. This topic contributes to strengthening the R&I ecosystem within the EU and supports the implementation of the “Strategy for European Life Sciences”. Given the importance of biotechnology as a critical technology, this topic aims to ensure that promising research results are efficiently taken further along the value chain, speeding the time to market or patient through stepwise funding and increasing the EU’s competitiveness.

The chosen area of focus is regenerative medicine as it has the potential to heal or replace tissues and organs damaged by age, disease, or trauma, as well as to normalise congenital defects. Proposals should focus on prototyping, demonstrating and validating health innovations from TRL 5, moving beyond early-stage research to clinical development, testing, or eventual large-scale manufacturing. The previously funded EU research on which the proposal is build should be applicable to the field of regenerative medicine and should have clear exploitation potential and/or socio-economic benefits for the patients.

Development of novel vaccines for viral pathogens with epidemic potential

Opened

Code: 39592 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-04 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of vaccine-based antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of vaccines that can be adjusted to variants would provide a critical preparedness measure against future health threats, due to infectious disease epidemics or pandemics.

Towards climate resilient, prepared and carbon neutral populations and healthcare systems

Opened

Code: 39589 | Identifier Code: HORIZON-HLTH-2026-01-ENVHLTH-04 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

The health sector accounts for nearly 5% of global greenhouse gas (GHG) emissions and generates significant demands for energy and materials, as well as dangerous polluting streams. Proactive mitigation efforts in the health sector can significantly reduce GHG emissions and pollution, saving many lives and contributing to relieve pressures on biodiversity and ecosystem services. However, specific mechanisms for emission reductions in the health sector remain less defined compared to those in other sectors.

Regulatory science to support translational development of patient-centred health technologies

Opened

Code: 39585 | Identifier Code: HORIZON-HLTH-2026-01-IND-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

The development, uptake and impact of health technologies typically results from a long product development process that is based on a ‘life cycle approach’ which typically involves several iterations of defined stages, i.e. from development, assessment to post-market surveillance and post-market clinical follow-up.

While health technologies are governed by comprehensive legal frameworks aiming to ensure that health technologies are safe and effective, the regulatory science underlying these legal frameworks needs to be updated.

This concerns inter alia 

1. more precise delineation of specific requirements (e.g. closing existing gaps concerning sufficiency of clinical evidence) and
2. the consideration of novel biomedical approaches, data and digital solutions (e.g. artificial intelligence – AI, virtual human twin, new approach methodologies as well as methods that cut through these domains) which model and predict relevant biological parameters and exploit relevant end-points and novel (bio)markers for clinical diagnostic and prognostic predictions.

Such update of the regulatory science of health technologies should aim at supporting an effective adoption and uptake into routine use by health systems and end-users (healthcare providers, citizens), while maintaining guardrails to ensure that innovative health technologies are backed up by evidence of sufficient quality and relevance to the human situation.

Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

Opened

Code: 39583 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Microbial infections can lead to long-lasting consequences on patients’ quality of life, leading to long-term conditions characterised by persistent inflammation, organ damage, and impaired functional capacity, which pose a growing public health and economic challenge.

These conditions are insufficiently understood, underdiagnosed, and lack effective treatments.

Advancing research into their prevention, treatment and management is essential to improving patient outcomes, reducing healthcare burdens, and strengthening workforce productivity.

Identifying and addressing low-value care in health and care systems

Opened

Code: 39580 | Identifier Code: HORIZON-HLTH-2026-01-CARE-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Low-value care, as defined in the footnote, can have widespread negative consequences for patients, caregivers, healthcare professionals, the health and care system, and the broader environment. A 2017 OECD report estimated that “wasteful healthcare spending is common” and that “up to one-fifth of healthcare spending could be redirected towards better uses”.

Low-value care represents a significant challenge, contributing to waste, costs, misuse of resources, and inefficiencies. Addressing low-value care can free up and allow reallocation of valuable healthcare resources to other areas of need, thereby maximising health outcomes, improving health and care systems resilience, and reducing their environmental impact. In this context, a recent report by the Expert Group on Health Systems Performance Assessment (HSPA) establishes the methodological basis and metrics to identify, measure and reduce low-value care.

Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Opened

Code: 39577 | Identifier Code: HORIZON-HLTH-2026-01-TOOL-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

This topic aims to support the ongoing paradigm shift in biomedical research and safety assessment of chemical compounds by fully integrating NAMs across the entire research and regulatory spectrum, from basic discovery phase to clinical application, and regulatory testing of medicinal products and medical devices, and/or industrial and environmental chemicals.

Building public trust and outreach in the life sciences

Opened

Code: 39574 | Identifier Code: HORIZON-HLTH-2026-01-STAYHLTH-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Life science innovations significantly contribute to peoples’ daily life and to individual and social well-being. To foster public trust, people must understand how life sciences work and how these technologies may impact people’s lives.

Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

Opened

Code: 39571 | Identifier Code: HORIZON-HLTH-2026-01-DISEASE-02 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 10/02/2026 | End submission calls: 16/04/2026

Already before the COVID-19 pandemic, 1 in 6 people in the EU suffered from mental health issues. The economic costs of it are estimated at 4% of the Gross Domestic Product (GDP) and since then these figures worsened in particular among vulnerable groups such as children and adolescents or those at risk of discrimination. Digital technologies have the potential to enhance mental health for instance by providing access to information, support networks and therapy services.

However, there are indications that the excessive or misguided use of digital technologies, particularly among children and young adults, can negatively affect mental health and exacerbate mental disorders. There is an urgent need for more robust data to foster a safer, responsible and healthier use of digital technologies among children and young adults, prioritising the protection of their mental health.